Zimmer Biomet Holdings (ZBH) released key details for investors regarding their Q2 2025 earnings call. 11 analysts shared their perspectives on the company, which recently appointed Kevin Thornal as Group President of Global Businesses and Americas. The company's shares fell due to uncertainty surrounding tariffs impacting the 2025 profit forecast. Despite this, ZBH entered new credit agreements. The company also announced lower dividends, disappointing some investors. However, there is speculation of potential upside as per some analyst ratings. Notably, ZBH completed the acquisition of Paragon 28, potentially opening a significant market avenue. There is consensus that due to conservative accounting, the company's soft earnings may have been affected. However, strong cash flows might be necessary for a stance towards recovery. ZBH brought onboard Jehanzeb Noor as Senior Vice President, reinforcing the company's strategic and innovation position. The bearish outlook got cemented due to a decrease in its earnings outlook prediction, reaching a 52-week low. Despite these difficulties, some experts still consider ZBH among the top falling stocks with unusual volume, signaling potential for recovery.
Zimmer Biomet Holdings ZBH News Analytics from Thu, 31 Oct 2024 07:00:00 GMT to Wed, 09 Jul 2025 12:01:47 GMT -
Rating -2
- Innovation 3
- Information 3
- Rumor -3
